Atlas Capital Advisors’s Adverum Biotechnologies ADVM Stock Holding History

Atlas Capital Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-425	Closed	-$4.04K	–	897
2022 Q3	$4.04K	Buy	+425	New	+$5.58K	﹤0.01%	790
2022 Q2	–	Sell	-425	Closed	-$5.57K	–	972
2022 Q1	$5.57K	Hold	425	–	–	﹤0.01%	783
2021 Q4	$7.48K	Hold	425	–	–	﹤0.01%	754
2021 Q3	$9.22K	Hold	425	–	–	﹤0.01%	735
2021 Q2	$14.9K	Hold	425	–	–	﹤0.01%	684
2021 Q1	$41.9K	Sell	425 -220	-34%	-$26.4K	0.01%	509
2020 Q4	$69.9K	Buy	+645	New	+$79.8K	0.01%	439
2020 Q3	–	Sell	-20	Closed	-$4.18K	–	313
2020 Q2	$4.18K	Sell	20 -272	-93%	-$48.2K	﹤0.01%	644
2020 Q1	$28.5K	Buy	+292	New	+$34K	0.01%	487

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Atlas Capital Advisors's ADVM Position: Q4 2022 in Review

Atlas Capital Advisors sold out of Adverum Biotechnologies (ADVM) in Q4 2022, closing a stake of 425 shares — an estimated $4.04K sold.

Atlas Capital Advisors first reported a position in ADVM in Q1 2020 and held it in 9 quarters. The position peaked at $69.9K in Q4 2020. 59 funds tracked by Wall St. Rank hold ADVM as of Q4 2022.

Atlas Capital Advisors reported no remaining Adverum Biotechnologies position as of Q4 2022 after selling out during the quarter.
Atlas Capital Advisors sold 425 Adverum Biotechnologies shares in Q4 2022, an estimated $4.04K.
Atlas Capital Advisors first reported a position in Adverum Biotechnologies in Q1 2020 and held it in 9 quarters.
Atlas Capital Advisors's Adverum Biotechnologies position peaked at $69.9K in Q4 2020.
59 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2022.

Based on Atlas Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.